Campbell D J, Mitchelhill K I, Schlicht S M, Booth R J
St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
J Card Fail. 2000 Jun;6(2):130-9.
Heart failure is a common cause of hospitalization and death across the industrialized world. Improving the diagnosis and care of patients with heart failure is therefore likely to have a major impact on morbidity, mortality, and health care costs.
To determine the relation between cardiac function and plasma levels of amino-terminal brain natriuretic peptide precursor (NT-proBNP), plasma NT-proBNP levels and ventricular function (by radionucleotide ventriculography) were measured in healthy patients, patients with renal failure, patients with recent myocardial infarction, and patients investigated for cardiorespiratory symptoms. Plasma NT-proBNP levels were greater in healthy women (median, 1.5 fmol/mL; range, 1.0 to 13.8 fmol/mL; n = 34) than healthy men (median, 1.0 fmol/mL; range, 1.0 to 3.3 fmol/mL; n = 33; P = .012). NT-proBNP levels were elevated in subjects with renal failure (geometric mean, 314 fmol/mL; range, 18 to 5,800 fmol/mL) and were related to left ventricular ejection fraction (LVEF) (r = -0.86; P < .0001; n = 19). NT-proBNP levels were also related to LVEF in patients with recent myocardial infarction (r = -0.62; P = .0003; n = 29) and those investigated for cardiorespiratory symptoms (r = -0.56; P < .0001; n = 129). Applying an upper limit of normal of 5 fmol/mL for men and 15 fmol/mL for women (specificity, 100%), elevated plasma NT-proBNP levels had 100% sensitivity for the detection of LVEF less than 45% after myocardial infarction and 97% sensitivity for the detection of LVEF less than 45% in patients investigated for cardiorespiratory symptoms. NT-proBNP levels were also elevated in 87% of the patients with normal systolic function (LVEF > or = 45%) after myocardial infarction and in 87% of the patients investigated for cardiorespiratory symptoms with heart failure and normal systolic function (LVEF > or = 45%).
Plasma NT-proBNP level is a sensitive indicator of cardiac dysfunction, both in the presence and absence of systolic dysfunction, and may prove to be a useful tool for the identification and management of cardiac dysfunction in the general community.
心力衰竭是工业化国家住院和死亡的常见原因。因此,改善心力衰竭患者的诊断和护理可能对发病率、死亡率和医疗费用产生重大影响。
为了确定心功能与氨基末端脑钠肽前体(NT-proBNP)血浆水平之间的关系,我们测量了健康患者、肾衰竭患者、近期心肌梗死患者以及因心肺症状接受检查的患者的血浆NT-proBNP水平和心室功能(通过放射性核素心室造影)。健康女性的血浆NT-proBNP水平(中位数为1.5 fmol/mL;范围为1.0至13.8 fmol/mL;n = 34)高于健康男性(中位数为1.0 fmol/mL;范围为1.0至3.3 fmol/mL;n = 33;P = 0.012)。肾衰竭患者的NT-proBNP水平升高(几何平均数为314 fmol/mL;范围为18至5800 fmol/mL),并且与左心室射血分数(LVEF)相关(r = -0.86;P < 0.0001;n = 19)。近期心肌梗死患者(r = -0-62;P = 0.0003;n = 29)以及因心肺症状接受检查患者(r = -0.56;P < 0.0001;n = 129)的NT-proBNP水平也与LVEF相关。将男性正常上限设定为5 fmol/mL,女性为15 fmol/mL(特异性为100%),血浆NT-proBNP水平升高对检测心肌梗死后LVEF低于45%具有100%的敏感性,对检测因心肺症状接受检查患者中LVEF低于45%具有97%的敏感性。在心肌梗死后收缩功能正常(LVEF≥45%)的患者中,87%的患者NT-proBNP水平也升高;在因心力衰竭且收缩功能正常(LVEF≥45%)而接受心肺症状检查的患者中,87%的患者NT-proBNP水平也升高。
血浆NT-proBNP水平是心脏功能障碍的敏感指标,无论是否存在收缩功能障碍,并且可能被证明是在普通人群中识别和管理心脏功能障碍的有用工具。